zhejiang-medicine-will-develop-and-commercialize-ambrx-site-specific-antibody-drug-conjugate-adc-targeting-her2-positive-breast-cancer-arx788

Ambrx, Zhejiang, WuXi to develop cancer drug in China

  • China
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: US-based Ambrx and China-based Zhejiang Medicine (ZMC) announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most... Read more

fall-from-grace-glaxosmithkline-gsk-fires-dr-jingwu-zhang-senior-vp-of-its-shanghai-r-d-unit-for-publishing-fraud-data-in-nature

GSK fires Chinese R&D head for publishing fraud data in...

  • China
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: GlaxoSmithKline (GSK) has fired the head of its Chinese R&D unit, Dr Jingwu Zhang, after it was found in a probe that he had fabricated data in a 2010... Read more

mindray-medical-will-acquire-zonare-medical-systems-an-ultrasound-technology-leader-for-usd105-million

Mindray to acquire Zonare for $105 mn

  • China
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Mindray Medical has plans to acquire Zonare Medical Systems, an ultrasound technology leader in the high-end radiology segment for $105 million. Mindray's... Read more

fastest-50

Asia’s Fastest 50 bio-firms shine

  • China
  • |
  • Opinion
  • |
  • By Narayanan Suresh
  • |
  • 0 Comment

The annual list of Asia's fastest growing pharma companies, compiled painstakingly by the BioSpectrum Asia team, is out. A remarkable aspect of the growth of companies... Read more

hr-analysis-biospectrum-asia-top-20-survey

Asia faces an acute skills gap challenge

  • China
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 0 Comment

Shortage of skills and qualification among life science professionals to pursue risk laden activities is proving to be a hurdle for Asia to emerge as a center of... Read more

ms-samantha-su-director-services-and-biomedical-spring-singapore-and-mr-simranjit-singh-chairman-biosingapore

Samantha Su, Simranjit Singh: Finding skilled professionals...

  • China
  • |
  • Opinion
  • |
  • By Ms Samantha Su and Mr Simranjit Singh
  • |
  • 0 Comment

In the biomedical sector, the combination of latest technology and a strong business model is considered to be ideal. Theoretically, the synergy created between... Read more

mr-matt-kerr-senior-manager-hays-recruiting-worldwide

Matt Kerr: Tough task ahead for APAC HR managers

  • China
  • |
  • Opinion
  • |
  • By Mr Matt Kerr
  • |
  • 0 Comment

With rapid growth of life sciences industry in Asia, we have seen many success stories over the last decade. However, any period of extensive growth is often accompanied... Read more

Biotech-310x175_copy

What were the top 20 M&A deals in pharma and biotech sector...

  • China
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 0 Comment

A majority of life science firms are standing on the edge of the patent cliff and their drug pipelines are experiencing acute scarcity. This is making them seek... Read more

Biotech-310x175_copy

What were the top 20 global M&A transactions of 2012?

  • Singapore
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 0 Comment

A majority of life science firms are standing on the edge of the patent cliff and their drug pipelines are experiencing acute scarcity. This is making them seek... Read more

Previous 1 3 4 5 6 7

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X